glp-1 employer coverage news october 2025 Perspectives from Employers on the Costs and Issues Associated with Covering Agonists for Weight Loss Trouble Getting Weight Loss Drugs

Ligand binding models provided logical explanations for SAR correlations

Plasma insulin (Alpco Diagnostics) and glucagon (Crystal Chem) levels were determined as per manufacturers instructions

This change would abruptly disrupt care for patients who are benefiting from GLP-1s

R (version 4.3.1

6 Over the next few years, the teams at MGH and University of Copenhagen independently tested the effects of supplemental GLP-1 in people and found that infusing its biologically active form stimulated insulin secretion and lowered blood glucose

Fact discovery on general causation must be completed by July 2, 2025, with expert reports exchanged in July and August